KDR and neoplasm: The impact of Ramucirumab on TAM has been observed, with its inhibition of VEGFR2 potentially leading to reduced TAM immune infiltration, as well as decreased release of cytokines and chemokines, thereby restraining tumor growth and proliferation [68].